Overexpression of miR-146a in basal-like breast cancer cells confers enhanced tumorigenic potential in association with altered p53 status

Carcinogenesis

Volumn 35, Issue 11, 2014, Pages 2567-2575

  Sandhu, Rupninder ^a   Rein, Jessica ^b   D'Arcy, Monica ^b   Herschkowitz, Jason I ^c   Hoadley, Katherine A ^a   Troester, Melissa A ^a,b,d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b IL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAGOMIR; FAS ASSOCIATED DEATH DOMAIN PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA 146A; PROTEIN P53; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; MICRORNA; MIRN146 MICRORNA, HUMAN; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER CELL LINE; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; PRIORITY JOURNAL; RNA INTERFERENCE; UPREGULATION; BIOSYNTHESIS; BREAST TUMOR; CARCINOGENESIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; METABOLISM; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CARCINOGENESIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICRORNAS; MUTATION; NF-KAPPA B; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84965190935     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu175     Document Type: Article

References (50)

1. Forbes, S.A. et al. (2011) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res., 39(Database issue), D945-D950.
2. Børresen-Dale, A.L. (2003) TP53 and breast cancer. Hum. Mutat., 21, 292-300.
3. Koboldt, D.C. et al. (2012) Comprehensive molecular portraits of human breast tumours. Nature, 490, 61-70.
4. Carey, L.A. et al. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295, 2492-2502.
5. Troester, M.A. et al. (2006) Gene expression patterns associated with p53 status in breast cancer. BMC Cancer, 6, 276.
6. Sørlie, T. et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA, 98, 10869-10874.
7. Langerød, A. et al. (2007) TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res., 9, R30.
8. Dumay, A. et al. (2013) Distinct tumor protein p53 mutants in breast cancer subgroups. Int. J. Cancer, 132, 1227-1231.
9. Olivier, M. et al. (2006) The clinical value of somatic TP53 gene mutations in 1, 794 patients with breast cancer. Clin. Cancer Res., 12, 1157-1167.
10. Troester, M.A. et al. (2004) Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res., 64, 4218-4226.
11. Suzuki, H.I. et al. (2009) Modulation of microRNA processing by p53. Nature, 460, 529-533.
12. Bartel, D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-297.
13. Miska, E.A. (2005) How microRNAs control cell division, differentiation and death. Curr. Opin. Genet. Dev., 15, 563-568.
14. Iorio, M.V. et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res., 65, 7065-7070.
15. Chang, T.C. et al. (2007) Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell, 26, 745-752.
16. Corney, D.C. et al. (2007) MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res., 67, 8433-8438.
17. Sachdeva, M. et al. (2009) p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc. Natl Acad. Sci. USA, 106, 3207-3212.
18. Yamakuchi, M. et al. (2010) P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc. Natl Acad. Sci. USA, 107, 6334-6339.
19. Georges, S.A. et al. (2008) Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Cancer Res., 68, 10105-10112.
20. Hu, W. et al. (2010) Negative regulation of tumor suppressor p53 by micro-RNA miR-504. Mol. Cell, 38, 689-699.
21. Le, M.T. et al. (2009) MicroRNA-125b is a novel negative regulator of p53. Genes Dev., 23, 862-876.
22. Park, S.Y. et al. (2009) miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat. Struct. Mol. Biol., 16, 23-29.
23. Yamakuchi, M. et al. (2008) miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl Acad. Sci. USA, 105, 13421-13426.
24. Fornari, F. et al. (2009) MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res., 69, 5761-5767.
25. Ghose, J. et al. (2011) Regulation of miR-146a by RelA/NFkB and p53 in STHdh(Q111)/Hdh(Q111) cells, a cell model of Huntington's disease. PLoS One, 6, e23837.
26. Blenkiron, C. et al. (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol., 8, R214.
27. Abboud, E.R. et al. (2007) Integrin-linked kinase: a hypoxia-induced antiapoptotic factor exploited by cancer cells. Int. J. Oncol., 30, 113-122.
28. Kucharczak, J. et al. (2003) To be, or not to be: NF-kappaB is the answer-role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene, 22, 8961-8982.
29. Bhaumik, D. et al. (2008) Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene, 27, 5643-5647.
30. Taganov, K.D. et al. (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl Acad. Sci. USA, 103, 12481-12486.
31. Ikner, A. et al. (2011) TWEAK induces apoptosis through a death-signaling complex comprising receptor-interacting protein 1 (RIP1), Fasassociated death domain (FADD), and caspase-8. J. Biol. Chem., 286, 21546-21554.
32. Hollstein, M. et al. (1994) Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res., 22, 3551-3555.
33. Soussi, T. et al. (2005) Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum. Mutat., 25, 6-17.
34. Carey, L.A. et al. (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res., 13, 2329-2334.
35. Sorlie, T. et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA, 100, 8418-8423.
36. Mouchawar, J. et al. (2010) Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res., 70, 4795-4800.
37. Ponomarev, E.D. et al. (2013) MicroRNAs are universal regulators of differentiation, activation, and polarization of microglia and macrophages in normal and diseased CNS. Glia, 61, 91-103.
38. Perkins, N.D. et al. (2006) Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ., 13, 759-772.
39. Dvinge, H. et al. (2013) The shaping and functional consequences of the microRNA landscape in breast cancer. Nature, 497, 378-382.
40. Liu, X. et al. (2009) MicroRNA-146a modulates human bronchial epithelial cell survival in response to the cytokine-induced apoptosis. Biochem. Biophys. Res. Commun., 380, 177-182.
41. Shen, J. et al. (2008) A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis, 29, 1963-1966.
42. Garcia, A.I. et al. (2011) Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol. Med., 3, 279-290.
43. Elstrodt, F. et al. (2006) BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res., 66, 41-45.
44. Luo, D. et al. (2013) A systematic evaluation of miRNA:mRNA interactions involved in the migration and invasion of breast cancer cells. J. Transl. Med., 11, 57.
45. Wang, X. et al. (2008) Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One, 3, e2557.
46. Pacifico, F. et al. (2010) Nuclear factor-(kappa)B contributes to anaplastic thyroid carcinomas through up-regulation of miR-146a. J. Clin. Endocrinol. Metab., 95, 1421-1430.
47. Li, Y. et al. (2010) miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res., 70, 1486-1495.
48. Yao, Q. et al. (2013) MicroRNA-146a acts as a metastasis suppressor in gastric cancer by targeting WASF2. Cancer Lett, 335, 219-224.
49. Khoury, M.P. et al. (2011) p53 isoforms: an intracellular microprocessor? Genes Cancer, 2, 453-465.
50. Soussi, T. et al. (2001) Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev. Cancer, 1, 233-240.